Evidence reviews - March 2026
The following documents contain the evidence that was used to develop the 2026 recommendations:
- Management of localised renal cell carcinoma using partial versus radical nephrectomy
- Management of localised renal cell carcinoma using non-surgical interventions or active surveillance
- Management of locally advanced renal cell carcinoma using nephrectomy or stereotactic ablative radiotherapy
- Information needs
- Monitoring of untreated renal lesions using active surveillance
- Follow-up of previously treated renal cell carcinoma
- Genetic assessment and management of renal cell carcinoma (RCC) associated with heritable RCC syndromes
- Management of advanced renal cell carcinoma using non-pharmacological interventions
- CT and MRI for diagnosing renal lesions in adults with suspected renal cell carcinoma
- Additional imaging tests for differentiating types of renal lesions
- Renal biopsy
- Risk prediction tools for localised and locally advanced renal cell carcinoma
- Risk prediction tools for metastatic renal cell carcinoma
Other supporting evidence
- Methods
- Economic analysis report on management of localised renal cell carcinoma using non-surgical interventions or active surveillance
- Economic model report for follow up and monitoring for previously treated renal cell carcinoma
This page was last updated: